Faron Pharmaceuticals Oy (AIM:FARN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
212.50
+12.50 (6.25%)
May 7, 2025, 4:35 PM GMT+1
70.52%
Market Cap 249.25M
Revenue (ttm) n/a
Net Income (ttm) -21.44M
Shares Out 124.62M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,403
Average Volume 144,618
Open 204.80
Previous Close 200.00
Day's Range 200.20 - 218.00
52-Week Range 85.00 - 290.00
Beta 1.06
RSI 47.65
Earnings Date Aug 27, 2025

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 25
Stock Exchange London Stock Exchange AIM
Ticker Symbol FARN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.